Guideline Atlas

What changed recently

Newly published and updated guidelines across every system, newest first. Each entry links to the official source.

Last 12 monthsLast 24 monthsAll time
All systemsCardiovascularRespiratoryGastrointestinal & HepatologyRenal & GenitourinaryEndocrine & MetabolicReproductive & Women's HealthHematology & OncologyMusculoskeletal & RheumatologyDermatologyNeurology & Special SensesPsychiatry & BehavioralImmunology & AllergyInfectious DiseaseEmergency & Critical CarePediatricsPreventive Medicine & Primary CareDental & Oral Health

10 older updates are outside this window. Show all time

  1. RespiratoryGLOBAL2026-05-0120252026
    Asthma

    The 2026 GINA report's headline addition is a set of four new flowcharts covering assessment, treatment and follow-up of acute asthma and exacerbations in adults, adolescents and children aged 6-11, in both primary and acute care settings. It also adds consensus guidance on which treatment step to start children aged 6-11 at, revised advice on biologics, oxygen saturation targets, SABA dosing and using ICS-formoterol instead of SABA for mild exacerbations, plus a stronger push to minimise oral corticosteroid exposure.

  2. RespiratoryGLOBAL2025-11-1020252026
    COPD

    The 2026 GOLD report widens the 'exacerbator' label so a single moderate or severe exacerbation in the past year now counts (previously two or more were needed), reframes the ABE assessment around disease activity, stability and control, revises the exacerbation-severity classification, and positions high-flow nasal therapy as a first-line respiratory support option in exacerbations. A new chapter on emerging technology and artificial intelligence in COPD was also added.